Skip to main content

Table 1 Clinical groups for first-line treatment stratification

From: Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

group

clinical presentation

0

clearly R0-resectable liver and/or lung metastases

1

unresectable liver and/or lung metastasis potentially resectable after downsizing, comorbidities allowing surgery

2

multiple metastasis, rapid progression, risk of rapid deterioration, unlikely to become resectable

3

never resectable and no symptoms or risk of deterioration